| 期刊全稱(chēng) | Anticancer Drug Development Guide | | 期刊簡(jiǎn)稱(chēng) | Preclinical Screenin | | 影響因子2023 | Beverly A. Teicher (Vice President and Director of | | 視頻video | http://file.papertrans.cn/159/158487/158487.mp4 | | 發(fā)行地址 | Includes supplementary material: | | 學(xué)科分類(lèi) | Cancer Drug Discovery and Development | | 圖書(shū)封面 |  | | 影響因子 | This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute‘s high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earlies | | Pindex | Book 2004 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國(guó)際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-28 16:57
發(fā)表于 2025-3-21 19:27:24
